| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | MRNA | Common Stock | Options Exercise | $39,600 | +40,000 | +0.74% | $0.9900* | 5,451,946 | 07 Jun 2023 | Direct | F3 |
| transaction | MRNA | Common Stock | Sale | $4,510,187 | -35,872 | -0.66% | $125.73 | 5,416,074 | 07 Jun 2023 | Direct | F3, F4 |
| transaction | MRNA | Common Stock | Sale | $522,233 | -4,128 | -0.08% | $126.51 | 5,411,946 | 07 Jun 2023 | Direct | F3, F5 |
| transaction | MRNA | Common Stock | Options Exercise | $39,600 | +40,000 | +0.74% | $0.9900* | 5,451,946 | 08 Jun 2023 | Direct | F3 |
| transaction | MRNA | Common Stock | Sale | $2,745,330 | -22,215 | -0.41% | $123.58 | 5,429,731 | 08 Jun 2023 | Direct | F3, F6 |
| transaction | MRNA | Common Stock | Sale | $2,166,324 | -17,396 | -0.32% | $124.53 | 5,412,335 | 08 Jun 2023 | Direct | F3, F7 |
| transaction | MRNA | Common Stock | Sale | $48,711 | -389 | -0.01% | $125.22 | 5,411,946 | 08 Jun 2023 | Direct | F3, F8 |
| holding | MRNA | Common Stock | 9,050,372 | 07 Jun 2023 | See Footnote | F1 | |||||
| holding | MRNA | Common Stock | 6,564,880 | 07 Jun 2023 | See Footnote | F2 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | MRNA | Stock Option (Right to Buy) | Options Exercise | $0 | -40,000 | -15% | $0.000000 | 227,155 | 07 Jun 2023 | Common Stock | 40,000 | $0.9900 | Direct | F3, F9 |
| transaction | MRNA | Stock Option (Right to Buy) | Options Exercise | $0 | -40,000 | -18% | $0.000000 | 187,155 | 08 Jun 2023 | Common Stock | 40,000 | $0.9900 | Direct | F3, F9 |
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
| Id | Content |
|---|---|
| F1 | These shares are owned directly by Boston Biotech Ventures, LLC ("Boston Biotech"). The reporting person is the majority equity unit holder and the sole managing member of Boston Biotech. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. |
| F2 | These shares are owned directly by OCHA LLC ("OCHA"). The reporting person is the majority equity unit holder and the sole managing member of OCHA. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. |
| F3 | The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018, as last amended on March 15, 2022, and as further described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on May 24, 2022. |
| F4 | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $125.31 to $126.31. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F5 | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $126.32 to $126.92. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F6 | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $123.11 to $124.11. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F7 | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $124.12 to $125.08. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F8 | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $125.13 to $125.29. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F9 | This option is fully vested and exercisable. |